

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 8, delete the fifth full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

D¹ Figure 5 shows the actual amino acids sequence (SEQ ID NO: 6) of the human preproparathyroid hormone for which the DNA sequence (SEQ ID NO: 5) in clone pSShPTH-10 codes.

On page 8, delete the sixth full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

D² Figure 6 shows the sequence (SEQ ID NO: 7) of the MF α 1-hPTH fusion gene.

On page 8, delete the seventh full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

D³ Figure 7 shows the sequence (SEQ ID NO: 8) of the MF α 1-hPTH fusion gene with all possible combinations of the DNA coding for hPTH.

On page 9, delete the first full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

D⁴ Figures 9A-B show the purification of recombinant hPTH medium including: FIG. 9A, a chromatogram of the HPLC purification; in FIG. 9B a chromatogram of the HPLC purification of fractions 32 and 33 from panel 9A (the peak of the recombinant hPTH is indicated in black); an HPLC of one microgram standards hPTH (1-84); and a co-

chromatogram of the recombinant PTH from the first chromatogram and one microgram
D⁴ cont standard of hPTH.

On page 9, delete the second full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

D⁵ Figures 10A-G show construction of PPTH-M13-ΔEA/KQ.

On page 9 and bridging page 10, delete the last full paragraph, and replace this paragraph with the following in accordance with 37 C.F.R. §1.121. A marked up version showing changes is attached:

D⁶ Figure 13. Purity of purified hPTH (1-84,Q26). Yeast growth medium from yeast strain BJ1991 transformed with the expression plasmids pαUXPTH-Q26 were concentrated and purified by reversed phase HPLC as described in Experimental Protocol. The purity of the recombinant hormone was then analyzed by analytical HPLC (Panel A) and SDS PAGE (Panel B, lane 2). In Panel B the purified hPTH (1-84,Q36) is compared with the wild type hormone purified by two runs on HPLC (lane 3). The molecular weight marker in lane M is the same as in Figure 2. Lane 1 shows a reference PTH produced in *E. coli*.

IN THE CLAIMS:

In accordance with 37 C.F.R. § 1.121, please substitute for claims 24, 26, 29, 34 and 36 the following rewritten version of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

D⁷ 24. (Amended) A composition comprising recombinant human parathyroid hormone (hPTH) (1-84), wherein the hPTH is made by a process comprising the steps of:

(a) providing a microorganism comprising:

(1) a leader sequence corresponding to the DNA sequence encoding *Saccharomyces* mating factor α1 lacking the yeast STE13 recognition site; and